B

Binex Co Ltd
KOSDAQ:053030

Watchlist Manager
Binex Co Ltd
KOSDAQ:053030
Watchlist
Price: 15 990 KRW 1.2%
Market Cap: 522.6B KRW

Binex Co Ltd's latest stock split occurred on May 2, 2011

The company executed a 2-for-1 stock split, meaning that for every share held, investors received 2 new shares.

The adjusted shares began trading on May 2, 2011. This was Binex Co Ltd's 3rd stock split, following the previous one in Aug 7, 2009.

Last Splits:
May 2, 2011
2-for-1
Aug 7, 2009
1250-for-1131
Sep 20, 2005
299-for-279
Pre-Split Price
N/A
Post-Split Price
5 650
Before
After
Last Splits:
May 2, 2011
2-for-1
Aug 7, 2009
1250-for-1131
Sep 20, 2005
299-for-279

Binex Co Ltd
Stock Splits History

Binex Co Ltd Stock Splits Timeline
May 2, 2011
May 2, 2011
Split 2-for-1
x2
Pre-Split Price
N/A
Post-Split Price
5 650
Before
After
Aug 7, 2009
Aug 7, 2009
Split 1250-for-1131
x1.105216622458
Pre-Split Price
N/A
Post-Split Price
5 650
Before
After
Sep 20, 2005
Sep 20, 2005
Split 299-for-279
x1.0716845878136
Pre-Split Price
N/A
Post-Split Price
5 650
Before
After

Global
Stock Splits Monitor

Date Company Split Pre-Split Price Post-Split Price
Apr 29, 2025
Capita PLC
LSE:CPI
1-for-15
/15
12.74 12.74 GBX N/A
Apr 29, 2025
Capita PLC
XMUN:CTAA
1-for-15
/15
0.1502 0.1502 EUR N/A
Apr 29, 2025
S
Scan Inter PCL
SET:SCN
1-for-1
x1
0.42 0.42 THB 0.43 0.43 THB
Apr 29, 2025
S
Shaanxi Meineng Clean Energy Corp Ltd
SZSE:001299
1-for-1
x1
14.8 10.5846 CNY 10.63 10.63 CNY
Apr 29, 2025
F
Foxo Technologies Inc
AMEX:FOXO
1-for-10
/10
0.0084 0.0841 USD N/A
Load More

Binex Co Ltd
Glance View

Market Cap
509.2B KRW
Industry
Pharmaceuticals

BINEX Co., Ltd. engages in the manufacture and sale of pharmaceuticals. The company is headquartered in Busan, Busan. The company went IPO on 2001-08-07. The Company’s products include digestive system agents, circulatory system agents, ulcer agents, antacids, anti-inflammatory agents, analgesics, gastrointestinal (GI) tract regulators and antispasmodics, antiemetic drugs, antihistamines, laxatives, antihypertensive and urinary agents, antibacterial and antibiotic agents, cough and cold remedies, anti-diabetic medicines, ophthalmic solutions, vitamins, nutrients, as well as ointment, creams and others. The company also manufactures bio medicines and raw materials. The firm distributes its products within domestic market and to overseas markets.

Intrinsic Value
11 658.7 KRW
Overvaluation 27%
Intrinsic Value
Price
B
Back to Top